BioBridge Global making investments for big-time growth

BioBridge Global CEO Martin Landon is working to leverage strong revenue increases in 2017 into more ...

Legacy Leaders: Francisco Cigarroa

                Legacy Leader Dr. Francisco Cigarroa ...

CTRC patients enrolled in GenSpera cancer drug trial San Antonio Business Journal
March 28, 2011

The Cancer Therapy & Research Center has enrolled its first patient in a Phase 1 clinical trial using GenSpera's new G-202 chemotherapeutic agent.

Cancer drug company GenSpera Inc. said Monday that the first patient received a dosage of the company's experimental drug, G-202, at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio.

San Antonio-based GenSpera (OTCBB: GNSZ) is conducting Phase 1 clinical trials at the University of Wisconsin Carbone Cancer Center and now the CTRC.


Stay informed. Subscribe to BioMed SA news alerts.